Amphetamines to Counteract Opioid-Induced Sedation

  title={Amphetamines to Counteract Opioid-Induced Sedation},
  author={Phillip Corey and Amy M. Heck and Ron Weathermon},
  journal={Annals of Pharmacotherapy},
  pages={1362 - 1366}
OBJECTIVE: TO describe the data regarding the use of amphetamines and amphetamine derivatives to counteract opioid-induced sedation. SUMMARY: Sedation is a major dose-limiting adverse effect of opioid therapy for many patients. Several reports have evaluated the use of amphetamines and amphetamine derivatives, such as mazindol, dextroamphetamine, and methylphenidate, to counteract opioid-induced sedation, with limited results. CONCLUSIONS: General use of amphetamines for the treatment of opioid… 
9 Citations
Psychiatric agents and implications for perioperative analgesia.
Anticipating and treating opioidassociated adverse effects
Adverse events associated with opioid therapy, ranging from nuisance to therapy-limiting, are manageable when addressed quickly and appropriately and are safe and efficacious analgesics when these effects are considered.
Care in an Acute Care Setting
Palliative care is appropriate in all settings and for patients and families facing any life-threatening illness as well as those who experience sudden illness or accidents that result in death.
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial.
This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
Prioritising drugs for single patient (n-of-1) trials in palliative care
Single patient trials (SPTs) offer a potential means of obtaining the evidence necessary to support or refute the use of several of the drugs and interventions whose use is currently based on physician experience or anecdote alone.
Palliative care in an acute care setting.
  • P. Beach
  • Medicine
    Clinical journal of oncology nursing
  • 2004


Caffeine as an analgesic adjuvant.
Thirty clinical studies involving more than 10,000 patients conducted during the last 20 years have been analyzed to assess the value of caffeine as an analgesic adjuvant. Although most studies
Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients.
There are no clearcut indications for mazindol in terminal cancer patients and the drug was chosen as a more effective drug by the patients in ten cases and by the investigators in nine, while anxiety, appetite, and food consumption were significantly worse.
The pathology of drug abuse
For pathologists, pharmacologists, drug abuse specialists and toxicologists, this book covers stimulant, opiate and steroid abuse. Each section includes a detailed discussion of how the drug came to
Caffeine self-administration in humans: 2. A within-subjects comparison of coffee and cola vehicles.
With both cola and coffee at the commonly used doses, self-reported motivation to work was greater and drowsiness and laziness smaller with caffeinated than noncaffeinated beverages.
Counteracting driver sleepiness: effects of napping, caffeine, and placebo.
Caffeine and nap significantly reduced driving impairments, subjective sleepiness, and electroencephalographic activity indicating drowsiness in sleepy drivers during two 1-hr monotonous early afternoon drives in a car simulator.